COMMUNIQUÉS West-GlobeNewswire

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

20/02/2024 - 00:25

Global retina expert joins to support sozinibercept development and launch preparation MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage [...]

Preparatory documents for the General Meeting as of of March 25, 2024

19/02/2024 - 18:00

Combined General Meeting of March 25, 2024 Availability of preparatory documents Spineway informs its shareholders that they are invited to attend the Combined General Meeting to be held on Monday, March 25, 2024 at 16: [...]

Documents préparatoires à l'Assemblée Générale du 25 Mars 2024

19/02/2024 - 18:00

Communiqué de presse Ecully, le 19 février 2024 – 18h Assemblée Générale Mixte du 25 mars 2024 Mise à disposition des documents préparatoires Spineway informe ses actionnaires qu’ils sont invités à participer à l’ [...]

GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 janvier 2024

19/02/2024 - 17:46

GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 janvier 2024 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, [...]

Novo Nordisk A/S – Share repurchase programme

19/02/2024 - 15:29

Bagsværd, Denmark, 19 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April [...]

Teladoc Health Provides Updated Start Time for Fourth Quarter 2023 Earnings Call on February 20, 2024

19/02/2024 - 14:00

PURCHASE, NY, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Teladoc Health , Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced today that the conference call to review its fourth quarter 2023 results, [...]

Medigene to Present at Upcoming Conferences

19/02/2024 - 14:00

Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for [...]

BioCryst Launches ORLADEYO® (berotralstat) in Italy

19/02/2024 - 13:54

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized [...]

CMR Surgical hires industry leader to drive operations across Asia Pacific, the Middle East and Africa

19/02/2024 - 13:00

CMR Surgical hires industry leader to drive operations across Asia Pacific, the Middle East and Africa Sushobhan Dasgupta joins as President and Chief Commercial Officer for Asia Pacific, the Middle East and Africa [...]

Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland

19/02/2024 - 12:15

ORION CORPORATION PRESS RELEASE 19 FEBRUARY 2024 at 13:15 EET Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland Orion Corporation is evaluating the possible outsourcing of [...]

Transactions in connection with share buy-back program

19/02/2024 - 10:40

Company Announcement COPENHAGEN, Denmark; February 19, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted [...]

New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses

19/02/2024 - 10:00

The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone. A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access [...]

GN Store Nord A/S - Notice to convene the Annual General Meeting 2024

19/02/2024 - 09:03

GN Store Nord’s Annual General Meeting will be held on Wednesday, March 13, 2024, at 10:00 a.m. CET at the company’s address: Lautrupbjerg 7, 2750 Ballerup, Denmark. Please find attached the notice to convene the Annual [...]

Certa Therapeutics’ FT011 Granted US FDA Fast Track for the Treatment of Systemic Sclerosis

19/02/2024 - 09:00

MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces [...]

CMR Surgical hires industry leader to drive operations across Asia Pacific, the Middle East and Africa

19/02/2024 - 08:00

CMR Surgical hires industry leader to drive operations across Asia Pacific, the Middle East and Africa Sushobhan Dasgupta joins as President and Chief Commercial Officer for Asia Pacific, the Middle East and Africa [...]

BioPorto A/S to host investor meetings on 22 February 2024

19/02/2024 - 07:41

19 February 2024 News Release BioPorto A/S to host investor meetings on 22 February 2024 COPENHAGEN, DENMARK and BOSTON, Mass., 19 February 2024, BioPorto A/S (BioPorto or Company), an in vitro diagnostics company [...]

Vidac Pharma presents high efficacy in multiple solid tumor models for its next-generation cancer drug candidate and synergy with standard-of-care treatment in liver cancer organoids

19/02/2024 - 07:30

London (UK), February 19, 2024, 7:30 am CET – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of [...]

Vidac Pharma présente une efficacité élevée dans plusieurs modèles de tumeurs solides pour son candidat médicament anticancéreux de nouvelle génération, et une synergie avec le traitement standard des organoïdes du cancer du foie

19/02/2024 - 07:30

Londres (Royaume-Uni), 19 février 2024, 7:30 CET – Vidac Pharma Holding Plc (Hambourg et Stuttgart : T9G ; ISIN : GB00BM9XQ619 ; WKN : A3DTUQ) est une société biopharmaceutique d'oncologie de stade clinique, pionnière [...]

Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma

19/02/2024 - 07:00

The Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) was granted based on results from the randomized Phase II clinical trial NIPU, which showed improved overall survival with UV1 in combination [...]